Amalgamated Bank Buys 2,368 Shares of Sotera Health (NASDAQ:SHC)

Amalgamated Bank increased its position in shares of Sotera Health (NASDAQ:SHC) by 3.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 72,715 shares of the company’s stock after acquiring an additional 2,368 shares during the period. Amalgamated Bank’s holdings in Sotera Health were worth $995,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. increased its stake in shares of Sotera Health by 164.3% in the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after buying an additional 1,140 shares during the period. True Wealth Design LLC acquired a new stake in Sotera Health during the 3rd quarter worth approximately $32,000. GAMMA Investing LLC grew its holdings in Sotera Health by 37.5% during the 4th quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock worth $56,000 after acquiring an additional 1,121 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in Sotera Health in the 3rd quarter valued at approximately $91,000. Finally, iSAM Funds UK Ltd bought a new position in shares of Sotera Health during the third quarter valued at $259,000. Institutional investors and hedge funds own 91.03% of the company’s stock.

Sotera Health Stock Down 6.3 %

Shares of NASDAQ:SHC opened at $11.68 on Tuesday. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.08. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The business’s 50-day moving average is $13.42 and its 200-day moving average is $14.48. The company has a market capitalization of $3.31 billion, a price-to-earnings ratio of 46.72 and a beta of 1.91.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SHC. Barclays decreased their price objective on Sotera Health from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday. Citigroup raised their price objective on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on Sotera Health in a research note on Friday, December 6th. They issued a “neutral” rating and a $14.00 price objective on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a research report on Thursday, November 21st. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Sotera Health has a consensus rating of “Moderate Buy” and a consensus target price of $15.92.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.